HSP-130 + US-approved Neulasta + EU-approved Neulasta
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neutropenia
Conditions
Neutropenia
Trial Timeline
Aug 1, 2015 → Jun 1, 2016
NCT ID
NCT02629289About HSP-130 + US-approved Neulasta + EU-approved Neulasta
HSP-130 + US-approved Neulasta + EU-approved Neulasta is a phase 1 stage product being developed by Pfizer for Neutropenia. The current trial status is completed. This product is registered under clinical trial identifier NCT02629289. Target conditions include Neutropenia.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02629289 | Phase 1 | Completed |
Competing Products
20 competing products in Neutropenia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Micafungin | Astellas Pharma | Approved | 85 |
| pegfilgrastim | Kyowa Kirin | Phase 2 | 52 |
| HHPG-19K Injection | Jiangsu Hengrui Medicine | Phase 3 | 77 |
| caspofungin acetate + Comparator: AmBisome | Merck | Phase 2 | 52 |
| Imipenem + Imipenem | Merck | Approved | 85 |
| Posaconazole IV solution + Posaconazole powder for oral suspension | Merck | Phase 1 | 33 |
| Ceftolozane-Tazobactam + Meropenem | Merck | Approved | 85 |
| Ceftolozane-tazobactam IV | Merck | Approved | 85 |
| Daptomycin + Daptomycin | Merck | Phase 3 | 77 |
| pegfilgrastim | Amgen | Phase 3 | 76 |
| Neulasta (pegfilgrastim) | Amgen | Approved | 84 |
| Liposomal amphotericin B (AmBisome®) + Liposomal amphotericin B (AmBisome®) | Gilead Sciences | Approved | 84 |
| Filgrastim Hospira (US) + US-approved Neupogen® | Pfizer | Phase 1 | 32 |
| linezolid + vancomycin | Pfizer | Phase 3 | 76 |
| Anidulafungin | Pfizer | Phase 1/2 | 40 |
| Nivestim® | Pfizer | Pre-clinical | 22 |
| Antibacterial agent for the treatment of febrile neutropenia | Pfizer | Pre-clinical | 22 |
| Voriconazole | Pfizer | Phase 1/2 | 40 |
| Filgrastim Hospira (US) + U.S.-approved Neupogen® | Pfizer | Phase 1 | 32 |
| ciprofloxacin + cefepime | Bayer | Phase 3 | 74 |